US FDA Compliance Strategy: Meetings Replace Some Untitled Letters
FDA’s CDER compliance office may use in-person meetings instead of untitled letters to avoid bureaucratic delays when raising minor concerns.
You may also be interested in...
Ashley's many years in the Department of Justice’s Office of International Affairs should be a plus for agency's globalization efforts.
Jim O'Neill, a Silicon Valley investment manager, would be an unusual choice to head US FDA, not just because he isn’t a physician, but because he’s favored substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, who worked at HHS in the Bush administration, others suggest he could champion much-needed change at the agency.
FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.